Back to top
more

Johnson & Johnson (JNJ)

(Real Time Quote from BATS)

$155.41 USD

155.41
3,624,673

-0.06 (-0.04%)

Updated Nov 11, 2024 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (57 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks News

Should Invesco Large Cap Value ETF (PWV) Be on Your Investing Radar?

Style Box ETF report for PWV

J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa

The approval of J&J's (JNJ) Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma is based on data from the phase III THOR study.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to PFE, MRNA New COVID Jabs & More

LLY's phase III study shows that tirzepatide reduces the risk of developing type II diabetes. FDA approves PFE and MRNA's updated COVID-19 vaccine.

Johnson & Johnson (JNJ) Outperforms Broader Market: What You Need to Know

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $161.43, denoting a +0.79% change from the preceding trading day.

J&J (JNJ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy

The approval is based on late-stage study data wherein treatment with J&J's (JNJ) Rybrevant plus Lazcluze cut the risk of disease progression or death by 30% in certain NSCLC patients.

J&J (JNJ) to Boost MedTech Business With V-Wave Acquisition

Johnson & Johnson (JNJ) inks a definitive agreement to acquire V-Wave Ltd. for an upfront payment of $600 million. The deal is likely to strengthen the company's MedTech business unit further.

Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?

Style Box ETF report for HDV

Why Is Johnson & Johnson (JNJ) Up 2.4% Since Last Earnings Report?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sundeep Ganoria  headshot

Medicare Releases Negotiated Prices on 10 Expensive Drugs

Following negotiations between Medicare and participating drug companies, some of the world's biggest medicines will see price cuts of 38-79%. These lowered prices will be going into effect in 2026.

J&J's (JNJ) DePuy Synthes' TriLEAP System to Aid Ankle Surgery

Johnson & Johnson's (JNJ) DePuy Synthes announces the launch of its TriLEAP System, which is likely to provide better orthopedic solutions to foot and ankle surgeons.

Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up

Halozyme (HALO) reports better-than-expected second-quarter 2024 results. The company maintains revenue guidance for 2024. Stock rises in after-hours trading.

Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Bayer (BAYRY) Q2 Earnings In Line, Nubeqa, Kerendia Boost Sales

Bayer's (BAYRY) second-quarter earnings match the consensus estimate. Sales gain from the Pharmaceutical business' strong performance.

Indrajit Bandyopadhyay headshot

Intuitive Surgical (ISRG) Rises 5% Post Earnings: What's Next?

Intuitive Surgical (ISRG) is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.

Sheraz Mian headshot

The Market's Excessive Recession Fears

We comment on the ongoing market sell-off, in addition to featuring new research reports on Johnson & Johnson (JNJ), T-Mobile (TMUS) and Marsh & McLennan (MMC) and others.

TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up

TEVA reports better-than-expected second-quarter results, beating both earnings and sales estimates. Management raises the 2024 financial outlook. The stock climbs 6.2% in response.

GSK Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance

GSK's revenues benefit from strong growth across the Specialty Medicines and General Medicines segments. It raises guidance for earnings and sales for the full year.

Kinjel Shah headshot

How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?

Though J&J (JNJ) beat estimates for both earnings and sales in the second quarter, a new investor should avoid buying the stock right now due to its legal troubles.

AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View

AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.

Sundeep Ganoria  headshot

GSK Stock Before Q2 Earnings: To Buy or Not to Buy?

We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix to drive second-quarter sales performance.